Sai Parenterals Ltd Q4 FY26 Results

Summary

Sai Parenterals Limited reported robust financial performance for the quarter and fiscal year ended March 31, 2026. For Q4 FY26, consolidated revenue surged by 166.65% to ₹197.93 crore, while Profit After Tax (PAT) dramatically increased by 736.04% to ₹13.25 crore. The full fiscal year FY26 saw consolidated revenue grow by 140.37% to ₹380.99 crore and PAT rise by 45.52% to ₹14.37 crore. This strong growth was driven by CDMO exports, the successful integration of its new Australian subsidiaries, and strategic expansion initiatives including a successful IPO which raised ₹285 crore.

Key Highlights

1. 1

   Sai Parenterals Limited's consolidated revenue for Q4 FY26 soared by 166.65% to ₹197.93 crore compared to Q4 FY25.

2. 2

   Consolidated Profit After Tax (PAT) for Q4 FY26 dramatically increased by 736.04% to ₹13.25 crore.

3. 3

   For the full fiscal year FY26, consolidated revenue grew by 140.37% to ₹380.99 crore, with PAT rising 45.52% to ₹14.37 crore.

4. 4

   The company reported a consolidated EBITDA of ₹28.97 crore for Q4 FY26, representing a growth of 366.79% from the previous year.

5. 5

   Strategic business expansion included the addition of 88 product dossiers in regulated and emerging markets in FY26, alongside 5 product dossiers with TGA Australia by Noumed.

6. 6

   Sai Parenterals successfully completed its IPO in March 2026, raising ₹285 crore in primary funds.

7. 7

   The acquisition of a 74.6% controlling stake in Noumed on November 12, 2025, significantly strengthened the company's position in the Australian pharmaceutical market.